Loading company details...
Beta
Latest Form 4 (Apr 27, 2026): Manuel Litchman Md. (President, CEO and Interim CFO): Tax Withholding of 19 shares, $14.25.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 27, 2026 | Manuel Litchman Md., President, CEO and Interim CFO | Tax Withholding | 19 | $14.25 |
| Jan 5, 2026 | Fortress Biotech, Inc. | Grant/Award | 278,385 | n/a |
| Dec 30, 2025 | Neil Herskowitz | Sale | 247 | $237.61 |
| Dec 30, 2025 | Adam J. Chill | Sale | 4 | $3.82 |
| Dec 30, 2025 | David Jin | Purchase | 247 | $237.61 |
| Oct 1, 2025 | Fortress Biotech, Inc. | Grant/Award | 59,334 | n/a |
| Apr 28, 2025 | Manuel Litchman Md., President, CEO and Interim CFO | Tax Withholding | 27 | $33.48 |
| Apr 2, 2025 | Fortress Biotech, Inc. | Grant/Award | 67,806 | n/a |
| Jun 28, 2024 | Fortress Biotech, Inc. | Grant/Award | 575,191 | n/a |
| Jun 5, 2024 | Manuel Litchman Md., President and CEO | Tax Withholding | 1,396 | $488.60 |